Cutting-edge RNA and antibody therapies are emerging to address cardiovascular and allergic diseases. Shanghai Circode Biomed has advanced HM-2002, a circular RNA-based drug candidate for ischemic heart disease, entering clinical trials following regulatory approvals in China and the U.S. Separately, the International Center for Vaccinology developed an intranasal monoclonal antibody targeting mugwort pollen allergens, demonstrated to prevent hay fever and asthma symptoms in mouse models. This novel allergy treatment approach offers potential for fast-acting, needle-free precision therapies adaptable to other major aeroallergens.